论文部分内容阅读
Zhejiang Huahai Pharma-ceuticals Co.,Ltd.(HuahaiPharmaceuticals,SH:600521)was initially foundedin 1989,and was listed inShanghai Stock Exchange inMarch 2003.Huahai Pharmaceuticals,alarge scale modern pharma-ceutical group that integratesformulations,APIs(activepharmaceutical ingredients)and intermediates,has 10branches(subsidiaries)in theUnited States,Shanghai andHangzhou,and is headquar-tered in Linhai of Zhejiangprovince.Huahai Pharmaceuticals isone of the largest supplier ofpril products worldwide,withthe annual production capaci-ties of its dominating prod-ucts“captopril”and“enalapril”both ranking firstin the world.It is also the onlymanufacturer in the worldthat can realize commercialproduction of captopril,enalapril and lisinopril at thesame time,according to thecompany.In 2008,Huahai Phar-maceuticals realizedRMB719 million of revenueand 42.18% gross profit ratefrom one of its main busi-nesses APIs andintermediates,separately up11.55% and down 1.39 per-centage point from 2007;italso achieved RMB59.5 mil-lion of revenue and a grossprofit rate of 80.05% from an-other main business-formulations,rising 27.85%and 4.38 percentage point re-spectively from 2007.In thefirst quarter of 2009,thecompany’s total revenuegrew by 14.86% comparedwith the same period of 2008.
(Huahai Pharmaceuticals, SH: 600521) was initially founded in 1989, and was listed in Shanghai Stock Exchange in March 2003. Hahai Pharmaceuticals, a large scale modern pharma-ceutical group that integratesformulations, APIs (activepharmaceutical ingredients) and intermediates, has 10branches (subsidiaries) in theUnited States, Shanghai andHangzhou, and is headquar-tered in Linhai of Zhejiangprovince.Huahai Pharmaceuticals isone of the largest supplier ofpril products worldwide, with the annual production capaci-ties of its dominating prod-ucts “captopril ”and “ en ranking ”both ranking first in the world. It is also the only manufacturer in the world can now realize commercial production of captopril, enalapril and lisinopril at the same time, according to the company. 2008, Huahai Phar-maceuticals realizedRMB719 million of revenueand 42.18% gross profit rate from one of its main busi-nesses APIs and intermediates, separately up11.55% and down 1.39 per-centage point from 2007 ; italso achieved RMB59.5 mil-lion of revenue and a grossprofit rate of 80.05% from an-other main business-formulations, rising 27.85% and 4.38 percentage point re-spectively from 2007. the first quarter of 2009, thecompany’s total revenuegrew by 14.86% comparedwith the same period of 2008.